Early Phase Trial Participation Among Under-Served Groups: Barriers Measured at Screening

Authors

  • Razvan Preda-Muresan Department of Early Phase Research, Harghita Institute of Translational Medicine, Miercurea Ciuc, Romania Author
  • Nemanja Nedeljkovic Centre for Patient Involvement, Pomoravlje Institute of Molecular Therapeutics, Jagodina, Serbia Author
  • Danica Azzopardi Centre for Research Ethics, Qormi Institute of Translational Medicine, Qormi, Malta Author

DOI:

https://doi.org/10.5281/zenodo.22649341

Keywords:

Early Phase Trial Participation Among Under-Served Groups, Translational medicine; Evidence synthesis; Clinical implementation; Health services research

Abstract

Early Phase Trial Participation Among Under-Served Groups is an area of active development in translational medicine, with
evidence that has accumulated unevenly across its component questions. We review the current evidence base for early phase trial
participation among under-served groups, spanning analytical, clinical, implementation, governance, and economic dimensions,
focusing on where practice has converged and where it continues to vary, and set out the practical considerations relevant to a
service considering its adoption. We conclude that selective, context-specific use is best supported by the evidence currently
available, rather than uniform adoption or avoidance.

References

Alvez D, Dumitrescu A, et al. "Early Phase Trial Participation Among Under-Served Groups: a systematic review". J Transl Med 8(2011): 80-86. DOI: 10.3389/fdgth.2026.1896184

Brankovic K, Kowalczyk B, et al. "Early Phase Trial Participation Among Under-Served Groups: a methodological appraisal". Clin Pharmacol Ther 10(2014): 91-98. DOI: 10.3390/diagnostics15162117

Castellani R, Ristic C, et al. "Early Phase Trial Participation Among Under-Served Groups: a multicentre analysis". Nat Rev Drug Discov 12(2017): 102-110. DOI: 10.4103/jrpp.jrpp_20_65

Dumitrescu A, Andric D, et al. "Early Phase Trial Participation Among Under-Served Groups: a prospective cohort study". Trials 14(2020): 113-122. DOI: 10.3389/fdgth.2026.1763884

Eriksdottir B, Brankovic E, et al. "Early Phase Trial Participation Among Under-Served Groups: a randomised evaluation". Drug Discov Today 16(2023): 124-134. DOI: 10.2196/48297

Farkas I, Ionescu F, et al. "Early Phase Trial Participation Among Under-Served Groups: a consensus statement". Clin Cancer Res 18(2011): 135-146. DOI: 10.1007/s00330-025-12031-z

Grabowski P, Petrescu G, et al. "Early Phase Trial Participation Among Under-Served Groups: a retrospective analysis". BMJ Open 20(2014): 146-158. DOI: 10.3389/fdgth.2026.1699005

Hendriksen W, Wojcik H, et al. "Early Phase Trial Participation Among Under-Served Groups: a validation study". J Clin Epidemiol 22(2017): 157-170. DOI: 10.3389/fdgth.2026.1834800

Ionescu F, Foscarini I, et al. "Early Phase Trial Participation Among Under-Served Groups: a scoping review". Contemp Clin Trials 24(2020): 168-182. DOI: 10.2196/69678

Jankowiak G, Grabowski J, et al. "Early Phase Trial Participation Among Under-Served Groups: a health-economic analysis". Ther Innov Regul Sci 26(2023): 179-185. DOI: 10.7759/cureus.46454

Kowalczyk N, Novotna K, et al. "Early Phase Trial Participation Among Under-Served Groups: a systematic review". Br J Clin7 Pharmacol 28(2011): 190-197. DOI: 10.1016/j.ssci.2025.107028

Lindqvist U, Urbanek L, et al. "Early Phase Trial Participation Among Under-Served Groups: a methodological appraisal". PLoS Med 30(2014): 201-209. DOI: 10.2196/48633

Marchetti D, Doncheva M, et al. "Early Phase Trial Participation Among Under-Served Groups: a multicentre analysis". Lancet 32(2017): 212-221. DOI: 10.1371/journal.pone.0305949

Novotna E, Eriksdottir N, et al. "Early Phase Trial Participation Among Under-Served Groups: a prospective cohort study". N Engl J Med 34(2020): 223-233. DOI: 10.1371/journal.pdig.0000514

Ostrowski L, Lindqvist O, et al. "Early Phase Trial Participation Among Under-Served Groups: a randomised evaluation". JAMA 36(2023): 234-245. DOI: 10.17219/acem/208596

Petrescu S, Szabo P, et al. "Early Phase Trial Participation Among Under-Served Groups: a consensus statement". Nat Med 38(2011): 245-257. DOI: 10.7759/cureus.104086

Quintero B, Balogh Q, et al. "Early Phase Trial Participation Among Under-Served Groups: a retrospective analysis". Cell Rep Med 40(2014): 256-269. DOI: 10.1038/s41746-023-00852-5

Ristic C, Castellani R, et al. "Early Phase Trial Participation Among Under-Served Groups: a validation study". Clin Transl Sci 42(2017): 267-281. DOI: 10.1016/j.mayocpiqo.2022.09.004

Szabo J, Jankowiak S, et al. "Early Phase Trial Participation Among Under-Served Groups: a scoping review". Pharmacogenomics J 44(2020): 278-284. DOI: 10.1177/08404704241291226

Tarasov Q, Quintero T, et al. "Early Phase Trial Participation Among Under-Served Groups: a health-economic analysis". Regul Toxicol Pharmacol 46(2023): 289-296. DOI: 10.1093/medlaw/fwad013

Urbanek Z, Zielinski U, et al. "Early Phase Trial Participation Among Under-Served Groups: a systematic review". Drug Saf 8(2011): 300-308. DOI: 10.2196/89834

Vasquez A, Alvez V, et al. "Early Phase Trial Participation Among Under-Served Groups: a methodological appraisal". Ann Intern Med 10(2014): 311-320. DOI: 10.1007/s10916-024-02104-9

Wojcik H, Hendriksen W, et al. "Early Phase Trial Participation Among Under-Served Groups: a multicentre analysis". BMC Med 12(2017): 322-332. DOI: 10.3389/fdgth.2026.1896184

Zielinski O, Ostrowski Z, et al. "Early Phase Trial Participation Among Under-Served Groups: a prospective cohort study". Sci Transl Med 14(2020): 333-344. DOI: 10.3390/diagnostics15162117

Andric V, Vasquez A, et al. "Early Phase Trial Participation Among Under-Served Groups: a randomised evaluation". J Transl Med 16(2023): 344-356. DOI: 10.4103/jrpp.jrpp_20_65

Balogh E, Emmerich B, et al. "Early Phase Trial Participation Among Under-Served Groups: a consensus statement". Clin Pharmacol Ther 18(2011): 355-368. DOI: 10.3389/fdgth.2026.1763884

Chiriac F, Farkas C, et al. "Early Phase Trial Participation Among Under-Served Groups: a retrospective analysis". Nat Rev Drug Discov 20(2014): 366-380. DOI: 10.2196/48297

Doncheva M, Marchetti D, et al. "Early Phase Trial Participation Among Under-Served Groups: a validation study". Trials 22(2017): 377-383. DOI: 10.1007/s00330-025-12031-z

Emmerich T, Tarasov E, et al. "Early Phase Trial Participation Among Under-Served Groups: a scoping review". Drug Discov Today 24(2020): 388-395. DOI: 10.3389/fdgth.2026.1699005

Foscarini C, Chiriac F, et al. "Early Phase Trial Participation Among Under-Served Groups: a health-economic analysis". Clin Cancer Res 26(2023): 399-407. DOI: 10.3389/fdgth.2026.1834800

Alvez D, Dumitrescu A, et al. "Early Phase Trial Participation Among Under-Served Groups: a systematic review". BMJ Open 28(2011): 410-419. DOI: 10.2196/69678

Brankovic K, Kowalczyk B, et al. "Early Phase Trial Participation Among Under-Served Groups: a methodological appraisal". J Clin Epidemiol 30(2014): 421-431. DOI: 10.7759/cureus.46454

Castellani R, Ristic C, et al. "Early Phase Trial Participation Among Under-Served Groups: a multicentre analysis". Contemp Clin Trials 32(2017): 432-443. DOI: 10.1016/j.ssci.2025.107028

Dumitrescu A, Andric D, et al. "Early Phase Trial Participation Among Under-Served Groups: a prospective cohort study". Ther Innov Regul Sci 34(2020): 443-455. DOI: 10.2196/48633

Eriksdottir B, Brankovic E, et al. "Early Phase Trial Participation Among Under-Served Groups: a randomised evaluation". Br J Clin Pharmacol 36(2023): 454-467. DOI: 10.1371/journal.pone.0305949

Farkas I, Ionescu F, et al. "Early Phase Trial Participation Among Under-Served Groups: a consensus statement". PLoS Med 38(2011): 465-479. DOI: 10.1371/journal.pdig.0000514

Grabowski P, Petrescu G, et al. "Early Phase Trial Participation Among Under-Served Groups: a retrospective analysis". Lancet 40(2014): 476-482. DOI: 10.17219/acem/208596

Hendriksen W, Wojcik H, et al. "Early Phase Trial Participation Among Under-Served Groups: a validation study". N Engl J Med 42(2017): 487-494. DOI: 10.7759/cureus.104086

Ionescu F, Foscarini I, et al. "Early Phase Trial Participation Among Under-Served Groups: a scoping review". JAMA 44(2020): 498-506. DOI: 10.1038/s41746-023-00852-5

Jankowiak G, Grabowski J, et al. "Early Phase Trial Participation Among Under-Served Groups: a health-economic analysis". Nat Med 46(2023): 509-518. DOI: 10.1016/j.mayocpiqo.2022.09.004

Kowalczyk N, Novotna K, et al. "Early Phase Trial Participation Among Under-Served Groups: a systematic review". Cell Rep Med 8(2011): 520-530. DOI: 10.1177/08404704241291226

Lindqvist U, Urbanek L, et al. "Early Phase Trial Participation Among Under-Served Groups: a methodological appraisal". Clin Transl Sci 10(2014): 531-542. DOI: 10.1093/medlaw/fwad013

Marchetti D, Doncheva M, et al. "Early Phase Trial Participation Among Under-Served Groups: a multicentre analysis". Pharmacogenomics J 12(2017): 542-554. DOI: 10.2196/89834

Novotna E, Eriksdottir N, et al. "Early Phase Trial Participation Among Under-Served Groups: a prospective cohort study". Regul Toxicol Pharmacol 14(2020): 553-566. DOI: 10.1007/s10916-024-02104-9

Ostrowski L, Lindqvist O, et al. "Early Phase Trial Participation Among Under-Served Groups: a randomised evaluation". Drug Saf 16(2023): 564-578. DOI: 10.3389/fdgth.2026.1896184

Petrescu S, Szabo P, et al. "Early Phase Trial Participation Among Under-Served Groups: a consensus statement". Ann Intern Med 18(2011): 575-581. DOI: 10.3390/diagnostics15162117

Quintero B, Balogh Q, et al. "Early Phase Trial Participation Among Under-Served Groups: a retrospective analysis". BMC Med 20(2014): 586-593. DOI: 10.4103/jrpp.jrpp_20_65

Ristic C, Castellani R, et al. "Early Phase Trial Participation Among Under-Served Groups: a validation study". Sci Transl Med 22(2017): 597-605. DOI: 10.3389/fdgth.2026.1763884

Szabo J, Jankowiak S, et al. "Early Phase Trial Participation Among Under-Served Groups: a scoping review". J Transl Med 24(2020): 608-617. DOI: 10.2196/48297

Tarasov Q, Quintero T, et al. "Early Phase Trial Participation Among Under-Served Groups: a health-economic analysis". Clin Pharmacol Ther 26(2023): 619-629. DOI: 10.1007/s00330-025-12031-z

Urbanek Z, Zielinski U, et al. "Early Phase Trial Participation Among Under-Served Groups: a systematic review". Nat Rev Drug Discov 28(2011): 630-641. DOI: 10.3389/fdgth.2026.1699005

Vasquez A, Alvez V, et al. "Early Phase Trial Participation Among Under-Served Groups: a methodological appraisal". Trials 30(2014): 641-653. DOI: 10.3389/fdgth.2026.1834800

Wojcik H, Hendriksen W, et al. "Early Phase Trial Participation Among Under-Served Groups: a multicentre analysis". Drug Discov Today 32(2017): 652-665. DOI: 10.2196/69678

Zielinski O, Ostrowski Z, et al. "Early Phase Trial Participation Among Under-Served Groups: a prospective cohort study". Clin Cancer Res 34(2020): 663-677. DOI: 10.7759/cureus.46454

Andric V, Vasquez A, et al. "Early Phase Trial Participation Among Under-Served Groups: a randomised evaluation". BMJ Open 36(2023): 674-680. DOI: 10.1016/j.ssci.2025.107028

Downloads

Published

2025-05-11

Issue

Vol. 4 No. 1 (2025): Vol 4 Issue 1 2025

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite

Early Phase Trial Participation Among Under-Served Groups: Barriers Measured at Screening. (2025). Translational Medicine & Therapeutics Journal, 4(1), 37-45. https://doi.org/10.5281/zenodo.22649341

Similar Articles

31-40 of 64

You may also start an advanced similarity search for this article.